Agilent Posts 32 Percent Jump in Q2 Revenues, Strong LC and Mass Spec Sales

Sales of the company's mass spec and LC platforms grew by more than 20 percent, as Life Science revenues rose to $464 million from $334 million a year ago.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.